4th Rare and Genetic Kidney Disease Drug Development Summit

With recent accelerated approval wins, positive clinical trial readouts, progression through clinical pipelines and exciting mergers and acquisitions, it has certainly been an industry-defining year for the rare and genetic renal space.

In the context of rapid progress and a mounting desire to propel game-changing novel therapies that will add to the arsenal of therapeutic options for patients, the 4th Rare and Genetic Kidney Disease Drug Development Summit returns to Boston. This unique event for the industry, academic KOL, and patient advocacy nephrology community provides an unrivalled opportunity to discuss acceleration of clinical advancements in orphan kidney disease populations.

This year's meeting brings together 30+ expert speakers, a two-tracked pre-conference workshop day and new content on podocyte biology, tissue bioengineering of kidney tissue models, market access strategies, as well as pricing and reimbursement conversations, across a breadth of rare renal therapeutic areas including FSGS, PKD, Alport Syndrome and IgAN to name but a few!

URLs:
Website: https://go.evvnt.com/2595572-0?pid=176
Tickets: https://go.evvnt.com/2595572-2?pid=176
Brochure: https://go.evvnt.com/2595572-3?pid=176

Prices:
Conference + Discover and Translational Workshops - Industry: USD 4197.00,
Conference + Clinical and Market Access Workshops - Industry: USD 4197.00,
Conference Only - Industry: USD 2999.00,
Conference + Discover and Translational Workshops - Academic: USD 3597.00,
Conference + Clinical and Market Access Workshops - Academic: USD 3597.00,
Conference Only - Academic: USD 2599.00,
Conference + Discover and Translational Workshops - Vendor: USD 5097.00,
Conference + Clinical and Market Access Workshops - Vendor: USD 5097.00,
Conference Only - Vendor: USD 3699.00

Speakers: Robbie McCarthy, USA General Manager, Advicenne S.A., B. Andre Weinstock, Research Director, Alport Syndrome Foundation, Stephen Olson, Senior Medical Director, Early Clinical Development, AstraZeneca, Weining Lu, Associate Professor, Boston University, Laurence H. Beck Jr., Nephrologist and David J. Salant MD Professor of Nephrology, Boston University, Richard Watt, Associate Professor and Chief Scientific Officer, Brigham Young University and REVITALE Pharma, Achim Obergfell, Global Medical Head Nephrology, CSL Vifor, Doug Paul, VP Commercial Strategy and Founder, Cypress BioPharma, Sumit Aggarwal, President and Chief Executive Officer, Eloxx Pharmaceuticals, Balaji Karthick Subramanian, Assistant Professor of Medicine, Harvard Medical School, Dongwon Lee, Assistant Professor of Pediatrics, Harvard Medical School, Friedhelm Hildebrandt, Professor of Pediatrics, Nephrology, Harvard Medical School, Dario Lemos, Assistant Professor of Medicine, Harvard Medical School and Brigham and Women's Hospital, Laurel Damashek, Executive Director, International Society of Glomerular Disease, Neel Anand, Senior Vice President, Research and Drug Discovery, Kezar Life Sciences, Susan Limb, Vice President, Clinical Science, Maze Therapeutics, Adele Rowley, Chief Scientific Officer, Mironid Ltd., David Feldman, Senior Medical Project Director, National Kidney Foundation, William Smoyer, VP, Nationwide Children's Hospital, Joshua Tarnoff, Chief Executive Officer, NephCure Kidney International, Jee Yeon Kim, Associate Clinical Research Medical Director (Renal), Novartis AG, Srini Srinivas, Senior Medical Director, Renal Diseases and Evidence Generation Lead, Novartis AG, Gerard Honig Associate Director, Biomarker Research, Otsuka Pharmaceutical Development and Commercialization, Inc, Michelle M. Richardson Director, Patient-Centered Research and Clinical Outcome Assessments, Otsuka Pharmaceuticals Development and Commercialization, Inc, Pille Harrison, VP Clinical Development, Purespring Therapeutics, John Seman, Chief Executive Officer, REVITALE Pharma, Chris Smith, President and Chief Executive Officer, SmithSolve LLC, Rachel McComb, Senior Clinical Operations Progam, Lead Rare GI2, Takeda Pharmaceutical, Kevin Fowler, Principal, The Voice of the Patient, Sean Eddy, Associate Research Scientist, NEPTUNE Match Molecular Profiling Lead, University of Michigan, Eloise Salmon, Clinical Assistant Professor, University of Michigan, Kerry Cooper, Senior Vice President Medical Affairs, Vera Therapeutics, Alex Duncan, Chief Scientific Officer, Walden Biosciences, Allen Davidoff, Chief Executive Officer, XORTX Therapeutics Inc.

Time: 8:00 am to 5:30 pm